Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 18/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20103364 | 1.00 | FFAR1 (0.49) | FFAR1 | |
| SCHEMBL15990271 | 1.00 | FFAR1 (0.49) | FFAR1 | |
| SCHEMBL15971969 | 1.00 | FFAR1 (0.49) | FFAR1 | |
| SCHEMBL17503182 | 1.00 | FFAR1 (0.49) | FFAR1 | |
| SCHEMBL15973334 | 1.00 | FFAR1 (0.49) | FFAR1 | |
| SCHEMBL19175526 | 1.00 | FFAR1 (0.49) | FFAR1 | |
| SCHEMBL17537791 | 0.95 | FFAR1 (0.45) | FFAR1 | |
| SCHEMBL19201873 | 0.95 | FFAR1 (0.45) | FFAR1 | |
| SCHEMBL17408842 | 0.86 | FFAR1 (0.45) | FFAR1 | |
| SCHEMBL22717214 | 0.85 | FFAR1 (0.49) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2958562-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4463451-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | Rezubio Pharmaceuticals Co., Ltd (CN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023134712-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | WO | disclosed |
| US-20220226298-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2022-07-21 | — | — | US | disclosed |
| EP-3976576-A1 | GPR40 AGONISTS | Kallyope, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022028317-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226298-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | FFAR1 10/4885 |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | GPR119, GLP1R, GPR65 | FFAR1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.